Ziopharm Appoints Kevin Boyle as Their New CEO
On Monday, August 30, Ziopharm announced (press release / webcast) the appointment of Kevin Boyle as their new CEO, with Heidi Hagen (interim CEO) returning to her position on the Board of Directors. Below, Celltelligence provides insights on how Boyle could help improve Ziopharm’s financial situation while regaining shareholders’ confidence.
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.